Description: Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Home Page: vimian.com
Riddargatan 19
Stockholm,
11457
Sweden
Phone:
Officers
Name | Title |
---|---|
Mr. Patrik Eriksson | Chief Executive Officer |
Mr. Carl-Johan Zetterberg Boudrie | Chief Financial Officer |
Ms. Maria Dahllof Tullberg | Head of IR, Communications & Sustainability |
Mr. Carl-Johan Ehn | General Counsel |
Mr. Bart Bremer | Chief People Officer |
Mr. Magnus Kjellberg | Chief Executive Officer of Nextmune |
Mr. Martin Bengtson | Head of M&A |
Mr. Stefano Santarelli | Chief Executive Officer of Indical Bioscience |
Mr. Guy C. Sporri | Chief Executive Officer of Movora |
Mr. Alireza Tajbakhsh | Head & CEO of VetFamily |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.7547 |
Price-to-Sales TTM: | 5.3232 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1100 |